InspireMD amended certain Series J and K warrants to align exercise terms with the anticipated FDA approval of its CGuard Prime 80 cm device. The amendments modified the exercise price to $0.7674 per share and set a termination date for the earlier of May 15, 2028 or 20 trading days following FDA approval announcement. These changes apply to approximately 4.8 million Series J shares and 9.5 million Series K shares held by participating warrant holders, including some board members. The company estimates potential gross proceeds of up to $11 million from full exercise, which would help fund the product launch. InspireMD operates in the medical device industry, developing carotid stent systems for stroke prevention.
